Answers are grounded in this paper and cite their sources.
In vitro study reveals that modulating the enzyme P4HB alters cellular and misfolded prion protein levels in neuronal cells, suggesting a potential therapeutic target for prion diseases.
Prions are misfolded, self-propagating versions of cellular proteins. In humans and animals, misfolding of the cellular prion protein (PrP C ) causes invariably fatal transmissible neurodegenerative diseases. Little is known about how mammalian prions replicate in the brain, including whether other proteins participate in prion replication in vivo . Several members of the protein disulfide isomerase family have been shown to reside in close spatial proximity to PrP C in cells and mice, implying that they could be involved in prion biogenesis. Here, we show that stable knock-down of the protein disulfide isomerase P4HB (also called PDIA1) in prion-susceptible CAD5 cells reduces PrP C levels and hinders the generation of protease-resistant PrP (PrP res ) following infection with two different prion strains. Moreover, transient knock-down of P4HB decreases PrP res levels in cells with established prion infection. Partial reduction of P4HB activity using the P4HB-selective inhibitor KSC-34 also decreases PrP C levels in uninfected CAD5 cells whereas treatment of prion-infected CAD5 cells with KSC-34 results in higher levels of PrP res . A proportion of P4HB reaches the cell surface where PrP C is located, and a secreted P4HB variant increases PrP res levels in cells. Collectively, these results suggest that P4HB influences PrP C homeostasis and modulates the conversion of PrP C into misfolded species. Thus, targeting P4HB during prion disease may have therapeutic benefit.
No takes yet. Share an insight, caveat, or question.
Amano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: